Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Eur Urol. 2015 Dec 24;70(4):566–573. doi: 10.1016/j.eururo.2015.12.006

Figure 2.

Figure 2

Estimated sensitivity and specificity of prostate cancer detection depending on screening strategy (prostate-specific antigen (PSA ≥3 ng/ml followed by systematic biopsy, PSA ≥3.0 ng/ml followed by targeted biopsy, and PSA ≥1.8 ng/ml followed by targeted biopsy). Bars indicate 95% confidence intervals for sensitivity (y-axis) and 1-specificity (x-axis).

* PSA = prostate specific antigen, Susp MRI = suspicious magnetic resonance imaging (see ‘Methods’ for details), SB = systematic biopsy, TB = targeted biopsy